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Medicare NCDs were equivalent to the corresponding private payer policies in 
51% of cases, more restrictive in 23%, less restrictive in 22%, and varied in 4%. 
Independence Blue Cross Group was the payer most often consistent with Medicare 
(82%), and WellPoint least often consistent (25%). We found little difference between 
510(k) cleared and PMA approved devices, although NCDs were more often less 
restrictive than the private payer policy for PMA approved devices than for 510(k) 
cleared devices (31% vs. 17%). We found few differences among devices by clinical 
indication. CONCLUSIONS: Medicare coverage of medical devices in NCDs is often 
inconsistent with coverage by private payers. For patients, this inconsistency means 
variable access to medical technology, and patients transitioning between health 
plans may face discontinuity of care. For industry, inconsistent coverage policy 
among payers adds uncertainty when designing clinical development programs, 
and when bringing innovations to market.
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OBJECTIVES: Due to the introduction of health exchanges in 2014, more than 7 
million Americans have gained access to commercial insurance. However, the per-
centage of potential enrollees covered by exchange-based plans varies widely by 
state. This study assesses the impact of economic, political, insurance industry 
and demographic variables on enrollment in plans offered on the exchanges, to 
identify the key factors likely to influence use of this more-affordable healthcare 
channel long term. METHODS: Enrollment in state-based exchange plans, par-
ticipation metrics, costs, and marketplace factors were obtained via census of 
148 U.S. health insurers. Demographic information was procured from the U.S. 
Census Bureau, and state-based political leanings were garnered from 2012 elec-
tion results. RESULTS: Correlation tests show that no single variable predominantly 
drove enrollment in exchange-based plans in 2014, but instead reveal a number of 
influential factors working in unison. Enrollment at the state level correlated most 
positively with median age, possession of a bachelor’s degree or higher, and 2012 
presidential votes secured by President Obama. The average premium for com-
mercial coverage in states prior to the launch of exchanges showed a weaker posi-
tive correlation. The strongest negative correlations were average family size and 
higher uninsured rate at the time of healthcare reform. Business-related issues, 
such as the competitive mix in states and participation in exchanges, had limited 
impact. CONCLUSIONS: Enrollment in exchange-based healthcare plans in 2014 
was driven by a number of factors, none of which predominated. Data suggest that 
enrollment in exchanges outperformed in states comprising older, better-educated, 
and more liberal Americans, a group likely already predisposed to favor healthcare 
reform. Conversely, enrollment was lower in states housing larger families, and 
more uninsured citizens to start with. Overall, demographic rather than economic 
issues directly look set to drive participation in exchange-based health insurance 
in future years.
PHP125
usE of global data sEts to assEss innovation landscaPEs in 
EmErging marKEts
Ondere L., Garfield S.
GfK Custom Research, Wayland, MA, USA
OBJECTIVES: Global economies are still in recovery from the financial crisis, and 
both mature and emerging markets will need to continuously innovate and launch 
new products and services to succeed in the future. Developed markets have tra-
ditionally been the source of most biopharmaceutical innovations as well as the 
destination for the resulting health and economic benefits and there is a gap in 
research on emerging markets in this sector.[1] We sought to assess the level of 
innovation in the BRICs markets (Brazil, Russia, India, China) compared to the top 
five mature economies by GDP (United States, Japan, Germany, France, and the 
United Kingdom). METHODS: We indexed the nine countries across seven innova-
tion indicators (high technology exports (in USD, and as a percentage of manufac-
tured exports), patent applications, revenue received for use of intellectual property, 
R&D expenditure, R&D workforce, and scientific/technical journal articles), based 
on 10-year trends from 2003 to 2012. These indices were then used to calculate an 
innovation score for each country. RESULTS: Among the target established markets, 
France and Germany were tied for highest overall growth in innovation, followed by 
the US, then UK, and Japan. China was the clear innovation leader among emerging 
markets followed by India, then Brazil, and Russia. Overall, with the exception of 
Russia, emerging markets scored better than the established markets. China ranked 
first overall, India second and Brazil third while Russia was eighth only beating out 
Japan which took ninth place overall. CONCLUSIONS: While established markets 
have traditionally been thought to drive technological advances, emerging BRICs 
markets have thriving innovation landscapes and in future may play a significant 
role in the biopharmaceutical innovation landscape. [1] Rezaie R et al. “Emergence 
of biopharmaceutical innovators in China, India, Brazil, and South Africa as global 
competitors and collaborators”. Health Res Policy Syst. 2012; 10: 18.
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OBJECTIVES: Pharmacist collaborative drug therapy management (CDTM) in U.S. 
hospitals has room for growth despite regulations recognizing the practice and evi-
dence of CDTM improving patient outcomes. This study’s objectives were to 1) assess 
pharmacy directors’ perceptions of CDTM, and 2) compare current opinions of CDTM 
to those 10 years prior. METHODS: A self-administered written survey was mailed 
use CAM compared to men. The factors associated with CAM use were different for 
men and women. Medical providers may need to counsel women about the effec-
tiveness of CAM to treat their chronic conditions. Future research needs to evaluate 
the effectiveness of CAM therapies among women with multiple chronic conditions.
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OBJECTIVES: Integrated delivery models in the outpatient setting such as Medical 
Homes (MHs) require effective interprofessional communication and collaborative 
practice. Our objective was to evaluate the attitudes towards collaboration of nurses, 
general practitioners (GPs), and specialists practicing in newly established MHs in 
the Parma Local Health Authority, Italy. METHODS: The 15 item Jefferson Scale of 
Attitudes Toward Physician-Nurse Collaboration was administered electronically to 
172 physicians (66 GPs, 106 specialists) and 113 nurses practicing in 12 MHs, caring 
for an overall population of about 90,000 patients. Possible scores of the scale range 
from 15 to 60 with higher scores representing a more positive attitude toward col-
laboration. The scale also contains three factors that measure: a) shared education 
and teamwork; b) caring versus curing; c) physician authority. Categorical variables 
were compared with Chi square or Fisher’s exact tests; continuous variables were 
compared using t-tests or ANOVA, as appropriate. RESULTS: A total of 191 surveys 
(45 GPs, 59 specialists, 87 nurses) were completed for an overall 67% response rate. 
The mean total score among nurses (51.5, Standard Deviation 3.7) reflected a sig-
nificantly (p< 0.01) more positive attitude towards collaboration compared with GPs 
(47.8, SD 4.6) and specialists (45.3, SD 7.7). This hierarchy was observed consistently 
for all three factors with the exception of physician authority, upon which general 
practitioners’ and specialists’ each expressed strong perceptions of nurses as assis-
tants rather than collaborators. CONCLUSIONS: Nurses consistently conveyed posi-
tive responses, indicative of a willingness to collaborate and to take on additional 
responsibility within the MH environment in Parma Local Health Authority. GPs and 
specialists responded in agreement with most items, although lower scores sug-
gested a relative temperate attitude towards physician-nurse collaboration. Further 
research into interprofessional relationships within MHs is needed to inform policy 
and develop educational initiatives to build a necessary culture of team-based care.
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OBJECTIVES: Cost-utility analysis (CUA) has been extensively used to assess and 
convey health care intervention costs and health benefits. We examined the growth 
and characteristics of published English-language CUAs through 2012. METHODS: 
We analyzed data from the Tufts Medical Center Cost-Effectiveness Analysis 
Registry (www.cearegisty.org), which contains detailed information on more than 
4,000 English-language CUAs published in peer-reviewed journals. We summarized 
study intervention types, disease areas researched, funding sources, journals of 
publication and methodological practices over three time periods: 1990-1999, 
2000-2009, and 2010-2012. We also investigated the extent to which the number 
of CUAs focusing on each of several worldwide geographic regions was corre-
lated with regional disease burden. RESULTS: The number of CUAs published 
steadily increased over time, from 34 annually during the 1990s to 431 annually 
during 2010-2012. The number of CUAs published during 2012 (n= 538) exceeded 
the number published in 2011 (n= 372) by 45%. The proportion of CUAs targeting 
the US population declined from 61% during 1990-1999 to 35% during 2010-2012 
(p< 0.0001). Most interventions have focused on pharmaceuticals (47%), followed 
by surgery (13%), screening (12%) and medical procedures (12%). Of the diseases 
researched, cardiovascular disease is the most common (18% of all studies), fol-
lowed by cancer (15%) and infectious diseases (15%). During 1990-2012, 51% of 
CUAs performed probabilistic sensitivity analyses and 33% included acceptability 
curves. The proportion of CUAs funded by the drug industry varies substantially 
across journals. Investigators in low- and middle-income countries contributed 
an increasing number of published CUAs in recent years. Across all geographic 
regions, few CUAs have focused on injuries relative to their population bur-
den. CONCLUSIONS: Our review reveals considerable growth and some change 
in the cost-utility literature in recent years. The data suggest growing interest in 
cost-utility methodology, particularly in developing countries.
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OBJECTIVES: To determine the consistency of Medicare coverage of medical devices 
in national coverage determinations (NCDs) with coverage policies issued by U.S. 
private payers. METHODS: We used the Tufts Medical Center Medicare National 
Coverage Determination Database to identify medical devices considered in NCDs 
from 1999-2013. We categorized each device with respect to its FDA approval path-
way and clinical application(s). We compared coverage in the NCD with coverage 
in equivalent policies issued by the 16 largest private U.S. payers that make their 
policies publicly available. We categorized each NCD as: equivalent to the private 
payer policy; more restrictive than the private payer policy; less restrictive than the 
private payer policy; or, when restrictiveness differed across considered indications, 
as varied. RESULTS: Medicare considered 47 medical devices through NCDs. We 
identified 540 coverage policies issued by private payers for the included devices. 
